QICAOGANGMU vs Steroid Creams: Differences in Evidence, Use and Safety
QICAOGANGMU and topical corticosteroids compared
QICAOGANGMU and topical corticosteroids are different categories of topical product. Corticosteroids are established anti-inflammatory medicines used for conditions including eczema and psoriasis. QICAOGANGMU is a steroid-free botanical topical with a disclosed formula, independent batch-testing information and ingredient research covering inflammation, itch, cooling and topical sensory effects.
Quick reference: key differences
| Question | Topical corticosteroids | QICAOGANGMU |
|---|---|---|
| What is it? | Anti-inflammatory medicine available in multiple potencies | Steroid-free botanical topical |
| Main evidence base | Extensive medicine-specific clinical trials and guidelines | Ingredient research, traditional-use context and product-testing evidence |
| Skin atrophy | Recognized risk with stronger, prolonged or inappropriate use | Steroid-free formulation, so corticosteroid-induced skin atrophy is outside its mechanism |
| Topical steroid withdrawal | Can occur in some prolonged-use circumstances; diagnosis remains an evolving area | Adds no corticosteroid exposure |
| Testing transparency | Not relevant to steroid identity because the medicine is itself a corticosteroid | Finished-product laboratory testing can confirm named analytes in the tested batch |
How topical corticosteroids work
Topical corticosteroids activate glucocorticoid receptors and reduce inflammatory gene signaling. This can quickly decrease redness, swelling, itch and scale.
The AAD strongly recommends topical corticosteroids for atopic dermatitis. For plaque psoriasis outside intertriginous areas, the AAD also recommends topical corticosteroids and notes that use beyond 12 weeks can be considered under careful physician supervision. AAD eczema guideline AAD psoriasis guideline
What this means: topical steroids are established and effective medicines. Their risks are managed through appropriate potency, body-site selection and duration.
What QICAOGANGMU contains
The international formula declares:
- Cnidii Fructus - 3%
- Borneolum Syntheticum - 2%
- Sophorae Flavescentis Radix - 1.5%
- Stemonae Radix - 0.5%
- Menthol - 0.5%
- Water, glycerin and petrolatum as the cream base
What researchers found about selected ingredients
| Ingredient | What researchers found | What this contributes | Evidence |
|---|---|---|---|
| Ku Shen | Selected Sophora compounds reduced inflammation and improved psoriasis-like skin changes in experimental models | Anti-inflammatory skin research | PMID 38358770 |
| She Chuang Zi | Osthole reduced scratching through TRPV3 inhibition in experimental itch models | Itch-pathway research | PMID 30108138 |
| Borneol | Topical borneol produced greater pain relief than placebo in a randomized human study and has topical-delivery research | Human sensory evidence and formulation science | PMC5452010 |
| Stemonae Radix | Several isolated alkaloids reduced inflammatory signals in laboratory cells | Anti-inflammatory laboratory research | PMID 35295975 |
Skin thinning and other safety differences
Skin atrophy is a recognized corticosteroid adverse effect, especially with higher potency, prolonged continuous use, occlusion and thin-skin areas. This does not mean a properly used steroid course inevitably causes thinning.
A steroid-free botanical topical avoids corticosteroid-specific adverse effects such as steroid-induced skin atrophy. Overall tolerability still depends on the finished formulation and the individual user.
Children and sensitive sites
Topical corticosteroids can be used in children when appropriate potency and medical guidance are followed. Facial and fold areas generally require more careful potency selection because the skin is thinner and more absorbent.
For any botanical topical, pediatric or sensitive-site use should follow the product's current directions and age-specific guidance.
Topical steroid withdrawal
TSW is increasingly recognized in the medical literature. A 2026 review describes growing clinical and research attention, while a separate 2026 systematic review found that diagnostic criteria remain inconsistent and much of the evidence is still descriptive. PMID 41924752 PMID 42170112
The relevant distinction here is straightforward: a steroid-free product does not add corticosteroid exposure.
What QICAOGANGMU's corticosteroid testing shows
The declared international ingredient list contains no corticosteroid. A finished-product sample was also tested by TÜV SÜD PSB for eight named corticosteroids: Prednisone, Prednisolone, Betamethasone, Dexamethasone, Cortisone, Hydrocortisone Acetate, Triamcinolone Acetonide and Hydrocortisone.
The reported result was Not Detected for the substances in that panel at a 50 ppm detection limit.
See the Purity Assured page for the applicable test information.
Steroid-free treatment also includes conventional medicines
There are also well-established non-steroid medicines. For eczema these include topical calcineurin inhibitors, PDE-4 inhibitors, JAK inhibitors and AhR medicines. For psoriasis, vitamin D analogues, tazarotene and calcineurin inhibitors can play steroid-sparing roles.
This matters because choosing to reduce steroid exposure does not require choosing between corticosteroids and herbal products alone.
How the choice changes by body site and treatment goal
A short course of topical corticosteroid can make sense when rapid control of active inflammation is the main goal, especially when a clinician has selected the potency for the body site. A steroid-free approach may be preferred when someone is building a maintenance routine, wants to avoid additional corticosteroid exposure or is comparing products with different mechanisms.
Body site matters. Thin areas such as the face and skin folds absorb topical corticosteroids more readily than thicker areas such as the palms or soles. That is why the same steroid potency is not used interchangeably everywhere. Botanical topicals also need site-specific tolerability because menthol and plant ingredients can feel stronger on sensitive skin.
How to compare the two fairly
- Purpose: is the goal active disease treatment, maintenance skincare or symptom comfort?
- Evidence: compare medicine-specific clinical trials with ingredient and formulation research without treating them as the same evidence type.
- Safety: consider steroid potency and duration on one side, and individual botanical tolerability on the other.
- Testing: for steroid-free products, finished-product testing can add useful transparency about the named corticosteroids screened in a tested batch.
Frequently asked questions
Is QICAOGANGMU the same kind of treatment as a steroid cream?
No. The formulations and mechanisms are different. Corticosteroids are medicines that act through glucocorticoid receptors, while QICAOGANGMU is a botanical topical built around a different ingredient profile.
Can QICAOGANGMU replace hydrocortisone?
That depends on why hydrocortisone was prescribed, the severity and body site. A prescribed treatment should not be changed solely because another product is steroid-free.
Does being steroid-free mean there is no skin-thinning risk from corticosteroids?
Yes. Corticosteroid-induced atrophy requires corticosteroid exposure, so a genuinely steroid-free formulation avoids that specific mechanism.
Can I use both?
If both are being used on the same area, ask the prescriber or pharmacist how they should be spaced or layered because there is no universal timing rule for every topical combination.
Related articles
References and guidance
- American Academy of Dermatology. Atopic dermatitis clinical guideline. AAD guideline
- American Academy of Dermatology. Psoriasis clinical guideline. AAD guideline
- Myles IA, Ratley G. Topical steroid withdrawal: dissecting the controversy. 2026. PMID 41924752
- Choi H et al. An Updated Systematic Review of Topical Corticosteroid Withdrawal. 2026. PMID 42170112
- Keane FM et al. Analysis of Chinese herbal creams prescribed for dermatological conditions. BMJ. 1999. PMID 10037629